The acquisition will enable the organization to enhance its offerings and assist device makers, researchers, and clinicians in overcoming the challenges in the cardiovascular domain.
FREMONT, CA: ViVitro Labs, a cardiovascular device test equipment and related consulting services company, recently acquired ProtomedLabs SASU, a medical devices testing laboratory based in Marseille, France. The acquisition will merge the operations of the two companies under the name ViVitro Labs, potentially leading to the expansion of its presence in Europe and the enhancement of its contract testing and customization capabilities.
Karim Mouneimne, President of ProtomedLabs, said, "ProtomedLabs offers contract service activities in Europe that go beyond the heart valve testing provided by ViVitro. The merger allows us to enhance ViVitro's global offerings with new services for cardiovascular devices from implants to accessories. I'm very proud to lead our new group. The merger brings together highly skilled individuals with significant expertise in testing cardiovascular medical devices. I really feel inspired and energized by the depth and breadth of knowledge of my team."
ProtomedLabs SASU is an ISO 17025 accredited medical device testing laboratory based in Marseille, France, specializing in the delivery of turnkey engineering solutions in device testing for companies developing implantable and interventional cardiovascular devices. It was owned by Protomed SA, Strasbourg, France, an ISO 13485 certified contract service R&D company specialized in medical device design and development. Protomed has empowered the development of minimally invasive surgery, single-use devices, vascular and cardiac implants, and so on. Its fabrication lab includes prototyping machines, test benches, control equipment, and advanced CAD software.
Scott Phillips, Owner and CEO of the StarFish Group and CEO of ViVitro Labs, said, "This acquisition and merger reflects our commitment to growing ViVitro's resources, products and services to address evolving cardiovascular testing system needs for leading-edge researchers and organizations."
"Scott Phillips is absolutely correct. The market is evolving rapidly in an increasingly complicated and demanding regulatory environment. By joining resources, we will be in a much better position to address the challenges of tomorrow. Scott recognized the value of this merger early on and acted on it decisively," remarked Mouneimne.
ViVitro Labs offers advanced cardiovascular test equipment, including heart valve, LVAD, TAH, stent, and graft testing, and related laboratory testing and consulting services. It has clients in over 39 countries, including hundreds of organizations which have trusted the expertise, accuracy, and quality for more than 30 decades. ViVitro Laboratory Services holds ISO/IEC 17025 accreditation based on ISO 5840. Its products are manufactured by StarFish Medical. After the finalization of the acquisition, ViVitro will move its headquarters to Victoria, Canada, with Karim Mouneimne as the President of the combined organization.
"From the beginning, when we approached ViVitro in 2015, I have always known there was a strong synergy between the companies," Mouneimne said. "Both groups were driven by tackling difficult technical issues in cardiovascular device testing. This led the teams to develop test methods and equipment that are ISO 17025 accredited and used around the world. The latest FDA reference study on heart valve pulsatile flow testing is a clear example of how complicated this test, as well as accelerated fatigue and particulate matter evaluation testing, can be. All these tests require significant expertise with highly skilled people who understand the industry and the challenges that device makers, researchers and clinicians are facing. Helping companies solve testing challenges by using our equipment and customized testing strategies is part of ViVitro's unique heritage. We go beyond standard catalog items or services. Our new larger capacity will allow us to aggressively invest in our product lineup while expanding customized service offerings for clients across the cardiovascular industry."